Analyzing electronic health records with artificial intelligence: abstract highlights from day 1 of ISPOR Europe 2019
As part of our continuous coverage of the ISPOR Europe 2019 (2–6 November; Copenhagen, Denmark) meeting, we bring you our abstract highlights from the first day of the conference: electronic health records, breast cancer and more!
In a novel study, researchers from the University of Pécs and Syreon Research Institute (both Pécs, Hungary) have perfomed a systematic literature review evaluating methods used to process and analyze electronic medical and health record data. These data are routinely employed to model input variables for oncology decision–analytic models. Literature reviews were screened for study inclusion according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement, and their relevance.
The results of the analysis demonstrate that the use of artificial intelligence methods – including machine-learning techniques and support vector machines – successfully improve the real-world usability of electronic medical and health record data. These technologies offer improved determination of parameters to describe individuals’ health states, provide clinical decision support and aid in predicting mortality risks, amongst other benefits.
An team of European researchers have collaborated to evaluate the burden of advanced breast cancer across ten European countries – Bulgaria, Croatia, Czechia, Estonia, Greece, Israel, Latvia, Poland, Romania and the Slovak Republic. To do so, researchers employed a unified questionnaire covering the epidemiology of advanced breast cancer, patient mortality rates, treatment patterns and economic aspects, to collect data in each country independently before collating the data for joint analysis.
The results of this first ever study evaluating the burden of advanced breast cancer across multiple countries demonstrate that, whilst the diagnostics and treatment patterns of advanced breast cancer are similar across all participating countries, significant heterogeneity exists in the annual mortality rates, indirect costs and loss of productive years across the countries. These findings may have important impacts on decision making processes concerning healthcare resource allocation.
Cabozantinib is approved as a first-line treatment for intermediate- and poor-risk advanced renal cell carcinoma patients in the EU. This approval followed the demonstration that cabozantinib offers significantly improved progression-free survival compared with sunitinib in the CABOSUN trial. In network meta-analyses, cabozantinib has also demonstrated superior progression-free survival compared with all other tyrosine kinase inhibitors used as treatments for advanced renal cell carcinoma. In this study, an international team of researchers from Germany, London and France have conducted a systematic literature review, network meta-analysis of studies investigating ten, first-line therapies for advanced renal cell carcinoma – including the recently approved immunotherapy combination of ipilimumab plus nivolumab.
The results of the study confirm that cabozantinib offers significant benefits for improved progression-free survival for advanced renal cell carcinoma patients over all other first-line treatments investigated.